Open AccessPredicting of fentanyl-associated neurotoxicity in pancreatic cancer with clical, genetic model
Author(s) -
О. П. Боброва,
Н. А. Шнайдер,
М. М. Петрова,
С. Н. Зобова,
Ю. А. Дыхно,
С. К. Зырянов,
А. В. Бобров,
Р. Ф. Насырова,
Л В Липинский,
А. С. Полякова,
Olga Melnikova
Publication year - 2021
Publication title -
èksperimentalʹnaâ i kliničeskaâ gastroènterologiâ
Language(s) - English
Resource type - Journals
ISSN - 1682-8658
DOI - 10.31146/1682-8658-ecg-187-3-136-145
Subject(s) - medicine , neurotoxicity , pancreatic cancer , transdermal , fentanyl , opioid , genetic model , cancer , bioinformatics , oncology , pharmacology , toxicity , gene , biochemistry , chemistry , receptor , biology
Aim. To develop a model for the implementation of opioid - associated neurotoxicity in patients with pancreatic cancer based on an analysis of the relationship of clinical and genetic factors. Materials and methods. In 45 patients with pancreatic cancer, 54 clinical and genetic factors were studied for predicting the implementation of opioid-associated neurotoxicity, receiving a transdermal form of fentanyl. Results. A clinical genetic model of the implementation of opioid - associated neurotoxicity in patients with pancreatic cancer was developed using the example of a transdermal form of fentanyl Conclusion. The clinical genetic model for predicting the risk of opioid-associated neurotoxicity in patients with pancreatic cancer is important from the perspective of personalized medicine.